“More than a decade ago, we devised a genetic approach to generate immune cells, called T cells, that are specific for HER2, an antigen (or protein) present on a broad range of cancers including breast cancer, sarcomas and brain tumors,” said Dr. Nabil Ahmed in a news release. Dr. Ahmed added that the strategy involves the isolation and culture of T cells from cancer patients, while genetically modifying them with human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptors (HER2-CARs). The cells can then be infused back into patients and target HER2-positive tumor cells
HER2-specific T cells As An Immunotherapy In HER2-Positive Sarcoma (2015)
http://immuno-oncologynews.com/2015/...itive-sarcoma/